NICE does not recommend chlormethine gel to treat T-cell lymphoma in draft guidance
NICE has issued draft guidance that does not recommend chlormethine gel for mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL).
List view / Grid view
NICE has issued draft guidance that does not recommend chlormethine gel for mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL).
A Phase I trial conducted by Novavax to test NVX‑CoV2373, the company’s recombinant COVID-19 vaccine candidate, showed it elicited robust antibody responses.
Tinostamustine has been granted Orphan Drug Designation by the European Commission to the treatment of T-cell prolymphocytic leukaemia (T-PLL).
NICE has said commonly used treatments for chronic primary pain such as paracetamol have little or no evidence that they work and should not be prescribed for the condition.
Researchers have shown that symptoms in patients experiencing severe COVID-19 improved when given either sarilumab or tocilizumab, interleukin-6 inhibitors.
The UK government has written an open letter to medicine suppliers, outlining how supply can be maintained after the end of the Brexit transition period.
The FDA has updated its list of hand sanitisers to not use, including those with low levels of ethyl alcohol or isopropyl alcohol or with a dangerous presence of methanol.
The UK government reserved a production line at Wockhardt for 18 months to ensure the rapid fill finish of COVID-19 vaccines.
An initial 450,000 of Oxford Nanopore's LamPORE test will be used by the UK government as COVID-19 diagnostics, which yield results in under two hours.
The first patients have been dosed in Moderna's Phase III clinical trial of its mRNA vaccine candidate to protect against COVID-19.
Epidyolex, a cannabidiol oral solution, has been given approval by the FDA to treat seizures associated with tuberous sclerosis complex (TSC).
The National Institutes of Health in the US has awarded contracts to seven biomedical companies to develop and manufacture COVID-19 diagnostics.
Bavencio (avelumab) and Inlyta (axitinib) are recommended by NICE for the treatment of advanced renal cell carcinoma, available on the Cancer Drugs Fund.
Four APIs are being considered by the FDA for its bulk drug substances list for potential use by outsourcing facilities when compounding if there is a clinical need.
Abingdon Health's COVID-19 rapid antibody test has been registered with the UK's Medicines and Healthcare products Regulatory Agency.